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ABSTRACT 
Aging is a complex process that is not completely understood. The study of segmental 
progeroid syndromes such as Hutchinson-Gilford progeria syndrome (HGPS) has allowed 
us to connect the common genetic mechanisms that occur in normal physiological aging, 
with the cellular alterations presented by this severe premature aging syndrome. Since the 
identification of mutations in the lamin A/C coding LMNA gene that cause HGPS and 
other laminopathies, there has been an increasing interest in the potential role  of lamins in 
the normal aging process. Progerin, a mutant form of lamin A, has attracted particular 
great attention. LMNA mutations in HGPS activate a cryptic splice site, leading to an 
aberrant splicing of lamin A, which results in a lamin AΔ150 transcript and progerin. 
Recent research data, including the results presented in this thesis, provide support for the 
possibility of a shared mechanism between natural physiological aging and pathological 
aging occurring in HGPS. This shared mechanism could contribute to solving part of the 
aging puzzle. The overall aim of this thesis was to gain an increased understanding of 
potential common genetic mechanisms behind Hutchinson-Gilford progeria syndrome 
and normal physiological aging. For this purpose, the research was primarily designed to 
study the expression of LMNA and the global genome differential splicing in aging cells 
to investigate the potential relationships that link the genetic mechanisms found in HGPS 
to those occurring in normal physiological aging. 
In paper I, we develop an absolute quantification method to determine the overall 
expression levels of the LMNA gene transcripts lamin A, lamin C and lamin AΔ150 
(progerin) during the in vitro cell aging of primary dermal fibroblasts from HGPS patients 
and from age-matched and parent controls. We show that lamin C is the most highly 
expressed transcript and that the lamin AΔ150 transcript is present in unaffected controls 
at an approximately 160-fold lower expression level compared with HGPS patients. 
While the levels of lamin A and lamin C transcripts remained unchanged during in vitro 
cell aging, the lamin AΔ150 transcript increased in late passage cells from HGPS patients 
and parental controls, suggesting a similar mechanism in HGPS patients and unaffected 
donors during cellular aging. 
In paper II, we expand on the first study and continue to investigate the expression of 
progerin in unaffected cells from different age groups, evaluating progerin as an aging 
biomarker for cellular senescence. We utilize a newly developed progerin antibody and 
quantify the percentage of progerin-expressing cells in the early and late passages of cells 
aged in vitro. We found that well-defined nuclear expression of progerin in primary 
dermal fibroblasts that were aged in vitro is an extremely rare event (or below the 
detection limit of an immunofluorescence assay). Our results do not rule out the 
possibility of progerin being expressed during normal cellular aging but question 
progerin’s contribution to physiological cellular aging. 
In paper III, we investigate if the LMNA gene presents differential allelic expression, 
which could help to explain the phenotypic variability observed among HGPS patients 
and laminopathies in general. We made use of the rs4641C/T LMNA coding single 
nucleotide polymorphism (SNP) and developed an allele-specific absolute 
quantification method for the lamin A and lamin C transcripts. The contribution of each 
allele to the total transcript level was quantified in dermal fibroblasts from HGPS 
patients and unaffected controls. We show that the C allele is more frequently 
expressed, corresponding to a 70% of the total lamin A/C transcripts, and that the most 
common HGPS mutation, LMNA c.1824C>T, is found in both the C and T alleles, 
which could account for the phenotypic variability observed among HGPS patients.  
 
In paper IV, we investigate whether aberrant splicing events, such as that occurring 
both in HGPS and sporadically in unaffected individuals, become more frequent 
and widespread on a genome-wide level during normal physiological aging, 
hypothetically, as a result of a declined stringency of the splicing machinery. To 
analyze the effect of age on splicing, we used exon microarrays to investigate the 
global genome differential exon expression and detect alternatively spliced genes 
in tissues of normal aging mice and in cells from a HGPS mouse model. We show 
that aging affects splicing via a considerable number of genes displaying 
significant differential and increased splicing with age. The most significantly 
enriched biological functions with alternative spliced genes during normal aging 
included RNA processing and the spliceosome pathway. Additionally, progeria 
cells had primarily differential splicing of extra cellular matrix genes, and 
explorative network enrichment analysis identified the NF-κB complex as a 
potential common network node for HGPS and normal tissue aging.  
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1. INTRODUCTION 
 
1.1 AGING 
Aging is an unavoidable and very complex biological and multifactorial process that 
affects all organisms, during which molecules, cells and tissues accumulate damage over 
time, resulting in degenerated tissue functions, an increased probability of acquiring age-
related diseases and eventually senescence and death 2. Increasing our understanding of 
why we age has always fascinated humans, possibly due to a hidden subconscious hope 
of extending youth and reaching immortality. However, medical research is primarily 
focused on improving health and life quality for a constantly growing elderly population 
and on deepening our knowledge of age-related diseases. 
Due to the complexity of the aging process and despite the enormous amount of 
knowledge that the aging research field has produced, the molecular mechanisms 
causing physiological aging are not completely understood. Several theories explaining 
the causes of aging have been proposed, such as the mitochondrial free radical damage 
theory, the accumulation of random mutations, DNA polymerase errors and failures in 
the DNA maintenance machineries, epigenetic collapse, telomere shortening, stem cell 
depletion, chronic inflammation and environmental injuries 3. However, aging is most 
likely caused by a couple or a variety of these factors, as initiated by endogenous and 
external damage-inducing agents or events. Endogenously, the DNA slowly 
accumulates random mutations with time due to the natural imperfection of the DNA 
maintenance machineries. However, as a normal by-product, our own metabolism 
produces reactive oxygen species (ROS) in the mitochondria that damage the 
macromolecules and structures of the cell. More DNA damage is caused by external 
agents, such as radiation (UV, x-rays or gamma-rays), hydrolysis, toxins, mutagenic 
chemicals and viruses. Finally, the accumulation of DNA damage contributes to aging 
via genomic instability, apoptosis, senescence and cancer.  
There are several avenues of research in the study of aging. These include the study of 
cellular senescence, genes and mutations that affect lifespan in animal models, genes 
implicated in age-related disorders and diseases resembling premature aging (progeroid 
syndromes or progerias). In unimodal progeroid syndromes such as Alzheimer’s 
disease, there is one predominant aspect of the normal aging phenotype, whereas 
segmental progeroid syndromes involve multiple aspects of the aging phenotype that 
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affect several but not all tissues 4 e.g., Down’s syndrome, Werner’s syndrome (WS), 
and Hutchinson-Gilford progeria syndrome (HGPS). Several segmental progeroid 
syndromes (e.g., atypical-WS and HGPS) are caused by mutations in the LMNA gene 
(table.1) coding for lamin proteins, which are constituents of the nuclear lamina. 
Lamin proteins comprise part of a larger group of diseases collectively named 
laminopathies; the study of these proteins has not only increased the understanding of 
these disorders but also provided insights into the functions of the nuclear lamina, its 
interaction with the genome and the relationship of these diseases to normal 
physiological aging. 
 
1.2 HUTCHINSON-GILFORD PROGERIA SYNDROME 
 
Hutchinson-Gilford progeria syndrome, also referred to as progeria or HGPS (Online 
Mendelian Inheritance in Man, OMIM, #176670), is a disease characterized by 
premature/accelerated aging. It is a severe, lethal and very rare genetic disease with an 
incidence of 1 in 4-8 million live births 5-7; according to the Progeria research 
Foundation (PRF), 90 cases of living patients are currently identified worldwide (PRF 
2013; http://www.progeriaresearch.org/prf-by-the-numbers.html). Children affected 
with HGPS appear normal at birth. However, within the first year of life, these 
children present growth retardation, are short in stature and have a reduced rate of 
weight gain. They soon develop other clinical abnormalities such as alopecia, skeletal 
and dental abnormalities and changes in skin with scleroderma and the loss of 
subcutaneous fat 6. The average life expectancy in HGPS is 13 years, and most 
patients die from atherosclerosis leading to heart failure or stroke 6-8. 
 
1.2.1 Molecular basis of HGPS 
Classical HGPS is most commonly caused by de novo point mutations in codon 608 in 
exon 11 of the LMNA gene G608G or G608S (fig.1) 9-11. Both mutations activate a 
cryptic splice site in exon 11 that leads to the deletion of 150 nucleic acids from the 
lamin A mRNA (fig.1). This aberrant splicing event results in a truncated prelamin A 
isoform that lacks 50 amino acids at its C-terminus, referred to as lamin AD Both 
mutations activate a cryptic splice site in exon 11 that leads to the deletion of 150 
nucleic acids from the lamin A mRNA (fig.1). This aberrant splicing 
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eventwhich in turn is unable to remove the last 15 amino acids. This leads to an 
unprocessed form of lamin A that accumulates as a permanently farnesylated and 
carboxymethylated lamin A precursor (fig.3). More than 90% of children with 
classical HGPS are heterozygous for the p.G608G (c.1824C>T) point mutation in 
exon 11 of the LMNA gene 11. However, none of the mutations in codon 608 generate 
a perfect splice site; therefore, the full-length lamin A protein is also expressed to a 
large extent by the mutant allele (fig.1). 
 
Figure 1. HGPS mutation in the LMNA gene:  Schematic illustration of the LMNA with its 12 exons 
encoding for lamin A and lamin C domains. Exon 1-10 encodes lamin C and exons 1-12 encodes for 
lamin A with a terminal CAAX box. The HGPS (c.1824C>T, p.G6008G) mutation in exon 11 activates 
a cryptic splice site with the consequent deletion of 150 nucleotides (Δ150) from the mRNA.  
Untranslated region (in red).  
 
1.2.2. Cellular phenotype in HGPS 
Cells from HGPS patients present dysmorphic nuclei with aberrant and varying blebbed 
shapes 11-13. These cells have a thickened nuclear lamina, a loss of peripheral 
heterochromatin and a clustered positioning of the nuclear pore complexes. 12; 14. Dermal 
fibroblasts from HGPS patients show severe changes in nuclear shape including 
lobulations and a thickening of the nuclear lamina. The altered composition of the 
nuclear lamina in turn leads to the aberrant incorporation and localization of lamina-
associated proteins to the nuclear envelope. The disorganization of the nuclear lamina 
and lamin A interaction with lamina-associated domains (LADs) may contribute the 
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observed loss of the peripheral heterochromatin in HGPS cells and clustering of the 
nuclear pore complexes12 (fig.2). This also leads to the disorganization of 
heterochromatin, as well as to of numerous transcription factors15 . These effects may 
be responsible for the highly misregulated gene expression profiles and impaired DNA 
damage responde (DDR) observed in HGPS cells 16; 17. Expression of high levels of 
progerin in the nuclei is typical for HGPS cells. Progerin accumulation, abnormal 
lamin localization, the reduction of lamin B and lamin-associated polypeptide type 2 
(LAP2) proteins are features that also have been observed in HGPS 12; 18. These 
changes in the nuclear architecture become more severe as the cells age in culture; this 
severity appears to correlate with an increase in progerin expression 12. Additionally, 
recent data support the notion that progerin anchors to the inner nuclear membrane 
through its farnesyl group, causing the characteristic blebbing of the nuclei in HGPS 
cells during interphase 19. When the cell is dividing and the nuclei are disassembled, 
progerin localizes in cytoplasmic aggregates and membrane-like structures that 
interfere with chromosome segregation to generate binucleated cells 20 Many of these 
features can also be observed in normal senescent cells (fig.2). 
Figure 2. Premature senescense and genomic instability in segmental progeroid syndromes and 
normal cells. Normal senescent cells show farnesylated prelamin A (prelamin A), shortened telomeres 
(telomere), loss of heterochromatin (HC), altered gene-expression (transcriptional regulation, TR), and 
accumulation of double strand breaks (DSB). Cells from HGPS and RD patients show altered position 
of nuclear pore complexes or nuclear pore associated proteins with effects on nuclear import of proteins 
(NPC). (Rodriguez and Eriksson, 2010) 1 . 
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1.3 LAMINS  
Nuclear lamins are type V intermediate filament proteins that are believed to be the 
progenitors of all intermediate filament proteins 21. They primarily distribute in the 
nuclear lamina (fig.4), but can also be found in the nucleoplasm. Characteristic of 
intermediate filaments, lamins are able to form homopolymers that can assemble into 
higher order filaments, and their primary role has long been attributed to a structural 
function and the support of the cellular nuclei. Today, we also know that the 
dissociation and reassociation of lamins is necessary during mitosis and that their 
interaction with the chromatin and nuclear proteins plays a fundamental role during 
transcription and DNA replication.  
Lamins are composed of a globular N-terminal head domain, a central α-helical 
coiled-coil rod domain, and a globular C-terminal tail domain, all of which are 
involved in the lamin assembly 22 (fig.1 and fig.5). The tail and rod domains are 
involved in molecular interactions. The rod interacts laterally with other lamins, and 
the tail domain binds to chromatin, lamina-associated polypeptide 2 (LAP2) and 
emerin 15. The C-terminal tail domain contains a structural Ig-fold domain (411-553) 
23 and a nuclear localization signal (417-422) that is required for the localization of 
lamins to the nucleus 23 (fig.5). 
There are two types of lamins in mammals: A-type and B-type lamins. A-type lamins 
are encoded by the LMNA gene, while B-type lamins are encoded by the LMNB1 and 
LMNB2 genes. LMNB1 encodes for lamin B1 and is located on chromosome 5q23.3-
q31.1, while the LMNB2 gene encodes for lamin B2 and lamin B3 and is located on 
chromosome 19p13.3 24. The most important distinction between A-type and B-type 
lamins is that B-type lamins are expressed at all developmental stages and are 
indispensable for cell survival25, while A-type lamins are known to be 
developmentally regulated and are expressed in differentiated cells 26. 
 
1.4 THE LMNA GENE  
The LMNA gene is located on chromosome 1q21.2-q21.3 and encodes for the A-type 
lamins; the gene is composed of 12 exons. Exons 1-12 encode lamin A, and exons 1-
10 encode lamin C 27; 28, which are the 2 main isoforms (fig.1 and fig.5).  
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1.4.1 A-type lamins 
Besides lamin A and lamin C, there are additional minor isoforms (lamin C2 and 
lamin AΔ10). The lamin AΔ10 and lamin C2 isoforms have been detected in colon 
and several carcinoma cell lines or only in male germ cells 29; 30. Lamin A and lamin C 
are the primary protein constituents of the mammalian nuclear lamina, which is a 
complex structure that acts as a scaffold for protein complexes that regulate nuclear 
structure and functions. Interest in these proteins has increased in recent years with the 
discovery that mutations in LMNA cause a variety of human diseases (termed primary 
laminopathies), including progeroid syndromes and disorders that primarily affect 
striated muscle, adipose, bone and neuronal tissues.  
 
1.4.2 The post-translational processing of prelamin A  
Lamin A is synthesized as a precursor protein, prelamin A; similar to the B-type 
lamins, prelamin A contains a CAAX box for farnesylation (C: Cysteine, A: aliphatic 
amino acid, X: any amino acid) at the carboxyl terminal end 31; 32. The CAAX (CSIM) 
box is responsible for the initiation of a series of post-translational maturation steps 
(fig.3). First, a farnesyl group is added to the cysteine by a farnesyl transferase 
(FTase). In the second step, an endoprotease, Zmpste24/Rce1, cuts out the last three 
amino acids, AAX (SIM). Thereafter, a methyl group is fixed to the farnesylated 
cysteine, a process that is catalyzed by isoprenyl carboxymethyl transferase (Icmt) 33. 
In the final step of prelamin A l maturation, the last 15 amino acids are cleaved away 
from the carboxyl end by Zmpste24 (fig. 3). The cellular localization of this process 
remains debated, but it most likely occurs at the endoplasmic reticulum, releasing the 
protein from its association with the nuclear membrane in the final step 34-36 (fig.3). 
Due to that the HGPS mutation activates a cryptic splice, which splice away 150 
nucleotides on the prelamin A mRNA, the translated HGPS prelamin A (prelamin 
AΔ50) does not contain an important recognition site for the Zmpste24 enzyme 
(RSYLLG). This enzyme is normally needed in the last maturation step of prelamin A 
to cut away the 15 last amino acids, containing the farnesyl group. The result in HGPS 
patients, is that a truncated lamin A, which remains permanently farnesylated and 
carboxymethylated is produce in the HGPS cells. This abnormally processed lamin A 
is commonly referred to as progerin (farnesylated prelamin AΔ50 or lamin AΔ50) 
(fig.3). 
  7 
 
Figure 3. The post-translational processing of prelamin A.  The post-translational processing of normal 
prelamin A and prelamin AΔ50 in HGPS are shown. The multistep processing of prelamin A to mature 
lamin A, involve multiple steps to obtain mature lamin A. In HGPS the recognition site RSYLLG for 
Zmpste24 is missing and the last proteolytic cleavage, cannot take place, resulting in a permanently 
farnesylated and carboxymethylated lamin AΔ50 known as progerin. 
 
1.5 THE NUCLEAR LAMINA  
The nuclear envelope separates the nuclei from the cytoplasm and is composed of the 
outer nuclear membrane (ONM) and the inner nuclear membrane (INM), which are 
separated by the perinuclear space (PNS) 37 (fig.4). The ONM and INM display 
periodical junctions forming the nuclear pore complexes (NPC), which are 
multiprotein channels that regulate macromolecular trafficking across the nuclear 
envelope 38. Because the ONM has membrane continuity with the endoplasmic 
reticulum (ER), it contains ER proteins and ribosomes that are associated with its 
membrane. The INM has its own set of integral membrane proteins, many of which 
interact with the nuclear lamina (fig.4) 
The nuclear lamina, underlying the INM, is a filamentous meshwork composed of A- 
and B-type lamins and nuclear lamin-associated membrane proteins. The nuclear 
lamina determines the nuclear shape and gives mechanical support to the nuclei. 
Important functions of the nuclear lamina include providing anchoring sites for 
chromatin domains (contributing to its impact on gene silencing), nuclear pore 
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complex positioning, and anchoring nuclear envelope proteins and several regulatory 
proteins, including signaling molecules and DNA transcription factors 39. Additional 
functions are related to the lamina’s involvement in DNA synthesis, DNA repair, 
transcription and nuclear envelope assembly.  
Several studies have identified various proteins binding to the A-type lamins of the 
lamina, including the lamina-associated polypeptides (LAP1 and LAP2), the nuclear 
envelope spectrin repeat proteins (nesprin 1 and 2), the SUN proteins (SUN 1 and 2), 
emerin, actin, retinoblastoma protein (pRb), sterol regulatory element-binding protein 
1 (SREBP1), components of the RNA polymerase II-dependent transcription 
complexes and DNA replication complexes. Lamin A and lamin C together interact 
with the SUN and nesprin proteins to form the LINC complex, which physically links 
the nucleoskeleton to the cytoskeleton (fig.4). 
Other components of the nuclear lamina that are not known to interact with A-type 
lamins correspond to the lamin B receptor (LBR) and MAN1. The LBR is localized in 
the nuclear envelope inner membrane and contains a binding site for heterochromatin 
protein 1 (HP1). As with lamin A, LBR anchors the lamina and the heterochromatin to 
the membrane 40. LBR is thought to mediate the interaction between chromatin and 
lamin B with implications in gene silencing; mutations of this gene have been associated 
with autosomal recessive HEM/Greenberg skeletal dysplasia 41. MAN 1 resides in the 
inner nuclear membrane and shares a LEM domain with LAP2 and emerin 42. Little is 
known regarding MAN1 function, with the exception of its interaction with SMAD 
proteins in cell signaling. Emerin is known to interact with nuclear lamins, splicing-
associated and transcription-repressing factors, nesprin 1 and actin. Emerin also contains 
a binding site for the chromatin bridging protein barrier-to-autointegration factor 
(BAF); mutations in its gene (BANF1) have been identified as the cause of hereditary 
progeroid syndrome 43. Both HP1 and BAF provide links between INM proteins and  
the chromatin (fig.4) . 
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Figure 4. Components of the nuclear envelope and nuclear lamina. Underlying the inner nuclear 
membrane (INM) we find the nuclear lamina. (Red meshwork). The nuclear lamina is composed by 
lamins A, B and C. It interacts with the chromatin and several trans-membrane proteins of the INM. 
Through the LINC complex (Sun1/2, Nesprin ½), the lamina interacts with the cytoskeleton. The lamina 
plays a role in correct nuclear pore complex (NPC) positioning. The drawing was inspired by (Goldman 
et al., 200239; Stewart and Burke 200737).  
 
1.6 LAMINOPATHIES  
Laminopathies are a group of diseases caused by mutations in genes encoding or 
affecting protein components of the nuclear lamina. They can be divided into primary 
and secondary laminopathies. The vast majority of the identified diseases are caused by 
mutations in the LMNA gene and are therefore known as primary laminopathies; 
diseases caused by mutations in genes coding for B-type lamins (LMNB1 and LMNB2), 
lamin-binding proteins such as EMD, TMPO, LBR, LEMD3 and LAP2α or genes 
affecting the  prelamin A processing such as FACE1 in humans or Zmpste24 in mice are 
known as secondary laminopathies.  
 
1.6.1 Primary laminopathies 
At present, 464 different mutations from 2,251 subjects have been identified in the 
LMNA gene (www.umd.be/LMNA/) to cause a large number of severe genetic 
disorders, some of which may display some phenotypic overlap 15 (fig.5). Different 
mutations can often cause the same disorder, but more interestingly, the same mutation 
can cause more or less severe phenotypes in different individuals or even different 
disorders. The phenotypic variability of diseases caused by mutations in the LMNA 
gene has greatly encouraged studies on the role of lamin function in disease. The 
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primary laminopathies constitute several autosomal dominant and recessive genetic 
diseases and are often, depending on the phenotype, divided into muscular 
dystrophies, lipodystrophies, neuropathies and segmental progeroid syndromes  44; 45 
(fig.5). 
 
1.6.1.1 Muscular dystrophies  
The muscular dystrophies include Emery-Dreifuss Muscular Dystrophy (EDMD), 
Limb-Girdle Muscular Dystrophy (LGMD) and Dilated Cardiomyopathy (DCM). The 
muscular dystrophies are characterized by progressive skeletal and heart muscle 
weakness. Defects in muscle proteins, the death of muscle cells and the gradual loss of 
the muscles (replaced by scar tissue and fat) are typical clinical features. Patients with 
EDMD slowly show progressive contractures in their childhood and teenage years. 
Muscle weakness and wasting starts in the distal limb muscles. Most patients also suffer 
from cardiac conduction defects and arrhythmias 46; 47. Slowly progressive shoulder and 
pelvic muscle weakness and wasting followed by the development of contractures and 
cardiac disturbances are typical for LGMD 48. In DCM, affected individuals display 
impaired contractility, arrhythmias and conduction defects. The muscle weakness in 
DCM is a cardiac-specific dystrophy and does not affect the skeletal muscle 49; 50 (fig.5).  
 
1.6.1.2 Lipodystrophies 
Lipodystrophies are characterized by a generalized or localized loss of body fat. Within 
this group are Familial Partial Lipodystrophies (FPLD), generalized Lipodystrophies 
type 2 and Mandibuloacral Dysplasia (MAD). In FPLD, the loss of subcutaneous white 
adipose tissue is observed in the extremities, the trunk and the gluteal region, while the 
face, neck and abdominal region accumulates fat cells. FPLD 51; 52 and generalized 
lipodystrophy type 253 are associated with an increased risk of early endpoint 
atherosclerosis and the development of metabolic diseases such as high triglyceride 
levels in the blood (hyperglyceridemia) and insulin resistance, which leads to diabetes. 
Clinical characteristics for MAD include general lipodystrophy, the delayed closure of 
cranial sutures, dental crowding, joint contractures, mandibular and clavicular 
hypoplasia, acroosteolysis and insulin resistance. MAD patients also show short stature 
and alopecia 54; 55 (fig.5) and are sometimes also classified as a progeroid syndrome 
(table.1). 
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1.6.1.3 Neuropathies  
The neuropathy group of the laminopathies includes Charcot-Marie-Tooth disease type 
2B1 (CMT2B1). In this disease, the nerves that control the muscles are affected. CMT 
patients slowly lose normal use of their extremities because the nerves degenerate; the 
muscles in the extremities become weakened because of the loss of stimulation by the 
affected nerves 10. 
 
1.6.1.4 Segmental progeroid syndromes  
These syndromes are characterized to resemble several but not all phenotypic features 
of natural physiological aging. In recent years, the group of segmental progeroid 
syndromes caused by mutations in the LMNA gene has been expanding, and in 
addition to classical HGPS, this group includes atypical-HGPS, atypical-Werner 
syndrome (AWS), restrictive dermopathy (RD), and mandibuloacral dysplasia (MAD). 
While the majority of children with classical HGPS (described above) are 
heterozygous for the p.G608G (c.1824C>T) point mutation in exon 11 of the LMNA 
gene, there are several other less frequent mutations in the LMNA gene that have been 
found to cause atypical-HGPS. These patients have, in addition to the disease 
phenotypes observed in classical HGPS, phenotypes that are not observed in typical 
HGPS or that lack phenotypes of the classical form 11; 56-60. Atypical-WS has features 
that are similar to Classical Werner syndrome (WS ) (disease caused by mutations in 
WNR), but atypical-WS is caused by mutations in the LMNA gene and not in the same 
gene as classical WS 61. Classical WS, also known as adult progeria, is not a therefore 
not a laminopathy because it is caused by mutations in the WNR gene, which encodes a 
RecQ helicase 62. In WS , death usually occurs in the fifth or sixth decade of life due to 
atherosclerosis or neoplasia. Growth retardation manifesting from the second decade, 
cataracts, type 2 diabetes, osteoporosis, alopecia, sclerodermatous skin, the loss of 
adipose tissue and an increased likelihood for cancer are typical clinical features of WS 
63; 64. Restrictive Dermopathy (RD) is a lethal tight skin contracture syndrome. 
Intrauterine growth retardation, joint contractures, tight and rigid skin and prominent 
vessels are typical for this neonatal disease. Affected individuals die due to pulmonary 
hypoplasia and subsequent respiratory insufficiencies during gestation or early after 
birth 65-68. RD is most commonly linked to mutations in the ZMPSTE gene, which leads 
to a loss of function; however, RD has also showed to be caused by splice mutations in 
the LMNA gene that in turn also involve exon 11. 
	  12	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Figure 5. Distribution of mutations in the LMNA gene causing laminopathies. The conserved α-helical 
segments of the central rod domain marked with coil 1a, coil 1b, and coil 2. Numbers refer to residues in 
the primary sequence. Lipodystrophy mutations are clustered at exon 8, which codes for an Ig-like 
domain. The majority of lipodystrophy cases are caused by a mutation at p.482.  >90% of HGPS patients 
carry the de novo c.1824C>T, G608G mutation. CDM1A, dilated cardiomyopathy, type 1A; EDMD, 
Emery–Dreifuss muscular dystrophy; MLF, Malouf Syndrome; MDC, Muscular dystrophy, congenital; 
LGMD1B, limb girdle muscular dystrophy, type 1B; FPLD, Dunnigan familial partial lipodystrophy; 
MAD, mandibuloacral dysplasia; CMT2B1, Charcoot-Marie–Tooth disorder, type 2B1; AWS, atypical 
Werner syndrome; HGPS, Hutchinson–Gilford progeria syndrome. Picture was authorized from the 
authors to be used in this thesis. (McKenna et al., 2013)69 
 
1.6.2 Secondary laminopathies  
Secondary laminopathies are caused by mutations in genes other than LMNA such as B-
type lamin genes (LMNB1 and LMNB2), genes coding for prelamin A processing 
proteins such as FACE1/Zmpste24 (e.g. MAD and RD), or genes coding for lamin-
binding proteins such as EMD, TMPO, LBR and LAMD3.  
 
1.7 LAMINS’ INVOLVEMENT IN AGING 
 
Lamins define the nuclear shape of the cell; thus, abnormal nuclear morphology is a 
general landmark for most laminopathies. However, abnormal nuclear morphology is 
also common in cancer cells 70 71. Major changes in the nuclear architecture, similar to 
those observed in HGPS cells, also accompany aging in the nematode C. elegans72. In 
their study, age-related changes, primarily in non-neuronal cells, included progressive 
alterations of the nuclear shape with a loss of heterochromatin from the nuclear 
periphery and an abnormal distribution of nuclear envelope proteins as the wild-type 
animals became older. Additionally, the down regulation of the C. elegans lamin, Ce-
lamin, and lamin-interacting proteins resulted in earlier death, thereby establishing a 
fundamental link between lifespan, nuclear morphology and the composition of the 
nuclear envelope 72. More recently, the involvement of lamins in the invertebrate aging 
process has also been confirmed in D. melanogaster, where an aberrant nuclear shape 
and size increased with age. The same phenotype was also caused by the 
overexpression of the farnesylated lamin proteins, lamin B and Kugelkern, which in 
turn reduced the lifespan of adult flies 71; 73. Moreover, the results from C. elegans, D. 
melanogaster, Xenopus laevis egg and cultured mammalian cells suggest that 
disturbances in the structure of the nuclear lamina are associated with aging, which 
affects fundamental cell functions such as chromatin organization, gene regulation, 
DNA replication, transcription, cell signaling and cell proliferation 72-74. Since the 
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discovery that the LMNA mutations in exon 11 (which cause the most severe 
premature aging diseases in humans) generated the production of mutant lamin A 
(progerin), there has been exponentially growing interest in HGPS. The intensive 
study of HGPS cells has shown that progeria patients accumulate progerin and that the 
levels of progerin increase as cells age 12; 75. These increasing levels coincide with 
more severe changes in the nuclear architecture, and the severity and progression of 
the disease are correlated with the amount of progerin that is expressed in the affected 
cell 12; 76. 
 
1.8 PROGEROID SYNDROMES AND NORMAL AGING 
HGPS and WS are likely two of the most-studied human disorders that result in 
symptoms of premature aging. While HGPS affects children, WS is known as the adult-
onset segmental premature aging disease. Studies of these segmental progeroid 
syndromes have not only increased the understanding of these disorders but have also 
provided insights into the functions of the nuclear lamina, DNA repair, and normal 
physiological aging.  
Progeroid syndromes caused by mutations in the LMNA gene (HGPS, RD, some forms 
of atypical-HGPS, and MAD) arise due to defects in the lamin A maturation pathway 
and create a common phenotypic output, which is most likely sustained by a common 
pathological mechanism with the accumulation of an unprocessed lamin A precursor 
(table 1). 
As in HGPS, a mutation in the LMNA gene that activates the cryptic splice site, 
leading to the production of progerin, has been found in atypical-WS 77. However, the 
levels of progerin in atypical-WS were significantly lower than what is usually 
observed in HGPS. In atypical-WS, similarly misshapen nuclei and an atypical 
localization of lamin A/C are found 61. In normal cells, these lamins are localized to 
the lamina and internal foci in the nucleoplasma. However, in atypical-WS, these foci 
are not observed in the nucleoplasma61 .  
Abnormal lamin A/C distribution and misshapen nuclei are also observed in MAD 
patient cells 54; 78. Heterochromatin loss and thickened nuclear lamina, similar to what 
is observed in HGPS, has also been found in MAD 79. In cells from RD patients, the 
  15 
altered expression of lamin A/C and the accumulation of prelamin A have been 
observed67; 80, in addition to an abnormal nuclear structure, including an altered 
localization of the nuclear pore-associated proteins and altered nuclear protein 
importation 67; 80; 81.  
Additionally, cellular characteristics of human fibroblasts expressing progerin include 
genome instability such as increased γ-H2AX foci, due to replication fork stalling and 
accumulation of double strand breaks (DSB), continuous p53 activation, and defective 
cell proliferation due to cell cycle arrest 82-85. Furthermore, several studies have 
demonstrated the role of A-type lamins in telomere maintenance 86; 87. In HGPS 
fibroblasts, DNA damage foci are localized to the telomeres in association with 
senescence 87. Interestingly, it has recently been shown for normal cells,  that 
telomere-dependent senescence activates the cryptic splice site and progerin 
production, and that cells with progressive telomere shortening presents extensive 
changes in alternative splicing 88 supporting recent suggestions for an existing 
interplay between telomers and lamin A both in HGPS and normal aging. 
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1.9 EVIDENCE IMPLICATING PROGERIN IN NORMAL AGING 
 
The suggestion of a link between HGPS and normal physiological aging is due to 
recent reports that directly implicate progerin in normal aging.  
The first evidence of this came from a study performed on fibroblasts from healthy 
donors 83. In this study, it was demonstrated that the wild-type lamin A cryptic splice 
site in exon 11 (that when mutated leads to the expression of progerin in HGPS) was 
also sporadically used in healthy unaffected individuals. Additionally, the expression 
of the progerin transcript lamin AΔ150 in normal cells was reported for the first time 
and was lower (50-fold) than that of the HGPS samples. It was detected in fibroblast 
cultures, heart and liver tissues from young and old unaffected individuals, however, 
the levels of lamin AΔ150 did not increase with age. The inhibition of the cryptic 
splice site reversed the same age-related nuclear defects as those observed in HGPS 
and normal old cells such as the reduced heterochromatin-specific trimethylation of 
Lys9 on histone H3 (Tri-Me-K9H3) and the down-regulation of heterochromatin 
protein HP1γ 18; 83.  
This exciting discovery encouraged researchers to search for more evidence of the 
possible participation and functional role of progerin during normal aging. One year 
later, progerin was directly detected via immunofluorescence (IF) in a very small 
nuclei subpopulation of 4 normal human fibroblast cell lines, and the quantification of 
the percentage of progerin-positive cells in 2 of these cell lines revealed an increment 
with the passage number up to approximately 1.5-3.0% 20. The progerin antibody 
primary stained giant, binucleated and apoptotic nuclei; because several binucleated 
nuclei presented aberrant chromosomal segregation that was similar to that observed 
in HGPS, it was suggested that progerin could contribute to the normal aging process 
by inducing the same mitotic defects in both HGPS and normal aging 20. In another 
study, the hypothesis of progerin; altering mitosis and cell cycle progression was 
further confirmed in HGPS cells, where it was demonstrated that the stable 
farnesylation and carboxymethylation of progerin caused an abnormal adherence to 
the membranes during mitosis, thereby impairing the re-localization of nuclear 
envelope/lamina components in early G1 19. Additionally, they showed that the 
required phosphorylation of Rb for the G1/S cell cycle transition was absent in HGPS 
blebbed cells, while HGPS cells that were normally shaped had phosphorylated-Rb. 
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Together, these studies suggested that progerin could contribute to HGPS and normal 
aging by interfering with mitosis, nuclear assembly and cell cycle progression 19; 20.  
Later same year, it was demonstrated for the first time that the cryptic splice site in 
exon 11 of lamin A could be used in vivo in normal cells from human skin biopsies 89. 
Progerin mRNA was detected in all samples and remained constant with age, and the 
progerin protein appeared to accumulate in the elderly. Progerin accumulated 
specifically in the primary dermal fibroblasts and terminally differentiated 
keratinocytes. Progerin-positive fibroblasts first appeared near the basement 
membrane and spread throughout the dermis with advanced age. The progerin-positive 
cells were not randomly distributed in the skin, and the cell cultures that were derived 
from samples with a high number of progerin-positive cells presented in turn few 
positive fibroblasts in culture; thus, the authors suggested that fibroblasts with 
progerin expression in vivo could correspond to a terminally differentiated or 
senescent subpopulation 89. 
At this time, several questions had been raised regarding progerin expression in 
normal aging. While progerin had been detected in normal cells, it was not clear 
whether its expression increased during normal aging. The results from these few 
studies were somewhat contradictory. While progerin mRNA did not increase with 
advanced age in vitro or in vivo, the number of progerin-positive cells increased with 
advanced age in vivo. Additionally, the results regarding progerin accumulation in 
vitro were not completely convincing in some studies either due to questions regarding 
the amount of samples that had been tested, or whether adequate protein separation 
had been achieved on western blots, and regarding the specificity and sensitivity of the 
RT-PCR and qPCR assays.  
In paper I, we addressed some of these questions by designing a powerful absolute 
quantification assay for LMNA transcripts (including progerin mRNA) and enhanced 
protein separation Western 75. 
Evidence later came for progerin’s role in the cardiovascular disease (CVD) of HGPS 
patients and the cardiovascular aging of unaffected individuals of advanced ages 90. In 
non-HGPS subjects, the progerin-positive cells presented cytoplasmic punctate 
staining in some cells of the 3 layers of coronary arteries (primarily in adventicia) and 
were negative for vascular smooth muscle cell (VSMC) staining (SMA, smooth 
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muscle actin). However, HGPS patients had clear nuclear progerin staining in most 
VSMC, and progerin was well represented in all 3 layers (adventitial fibroblasts, 
VSMC of the media and intima, and endothelial cells). This study reaffirmed the 
hypothesis that a progerin-positive subpopulation increases in size with advanced age 
in additional cell types and in aging cardiovascular tissue. 90. Additional evidence that 
progerin-expressing cells in vivo can correspond to a subpopulation of terminally 
differentiated or senescent cells can be extrapolated from another recent study in 
which adult stem cells in HGPS expressed low levels of progerin in comparison with 
non-stem cells/differentiated cells 91.  
While it is known that mutations in exon 11 of the LMNA gene cause HGPS, it was not 
known until recent years what could be causing the increased progerin expression in 
circumstances of normal aging. In 2011, a study showed that telomere damage had a 
causative role activating the cryptic splice site. Progerin production was activated 
during the in vitro cell aging of normal fibroblasts in telomere-dependent cellular 
senescence. The authors proposed a model in senescent cells in which progressive 
telomere shortening together with the activation of p53 triggers a global alternative 
splicing, including lamin AΔ150 /progerin, which would in turn contribute to cellular 
senescence. The authors also presented some evidence for the extensive splicing 
events that occurred during senescence 88. 
 
1.10 SPLICING DURING DISEASE AND LIFESPAN  
 
1.10.1 Alternative splicing 
Alternative splicing (AS) is a major cellular mechanism with several functions in 
metazoans, primarily in generating proteomic variability 92. The majority of the genes 
undergo AS; it was previously thought that AS was an infrequent phenomenon, but 
more recent studies have reported AS to be highly widespread with approximately 74-
95% of the genes being alternatively spliced 93-96. AS has a universal role in genome 
evolution, developmental processes, tissue differentiation, and in regulating the 
transcriptome to influence the phenotype 97. There are different types of splicing events 
98 that normally occur in a regulated manner; however, as in HGPS, aberrant splicing 
can result in disease. More than 15% of all heritable human diseases have been known 
to be associated with mutations in splice sites or splicing regulatory elements 92, and a 
large proportion of human genetic disorders result from splicing variants 99. Abnormal 
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splicing variants are thought to contribute to the development of cancer 100-102. AS 
occur more often in transcripts from genes expressed in functionally complex tissues 
with diverse cell types, such as the brain and testis. In brain, AS is implicated in 
processes such as the control of synaptic plasticity associated with cognition and other 
neural processes 103-105. Alterations of the splicing machinery have shown to be 
causative of diseases such as cystic fibrosis 106 and neuropsychiatric disorders 107; 108.  
 
 The study of the transcriptome is important because many phenotypic changes, 
including splicing, are not detected at the gene expression level but can be detected by 
investigating AS at the exon expression level 109. 
 
1.10.2 Aging and altered global splicing 
Aging in HGPS and normal physiological aging have been associated with widespread 
changes at the gene expression level in multiple mammalian tissues16; 110. Aging is 
known to damage several cellular components such as the genome and 
macromolecules (that also may form part of the splicing machinery). However, very 
little is known regarding how aging affects the variability of the transcriptome through 
alternative splicing. Recently, some studies have presented results revealing a potential 
association between aging and genome-wide alterations of alternative splicing. Age-
related splicing has been identified in both normal individuals and patients with 
neurodegenerative diseases such as Alzheimer’s disease and frontotemporal lobar 
degeneration (FTLD) 11; 111. Additionally, another recent normal aging study in human 
and rhesus macaque brains using high-throughput transcriptomic sequencing, exon 
arrays and PCR identified widespread splicing changes with development and age in 
40% of the genes (of which 30% corresponded to age-related splicing and 70% to 
developmental splicing)112. However, in a transcriptomic microarray study of blood 
from aging subjects, few probes (2%) were robustly associated with age; there were 7 
age-associated pathways (including the processing of mRNA) 113.  It seems that recent 
studies points toward a potential effect of age on splicing, and most interestingly that 
progerin-induced senescense by telomere shortening show that normal cells with 
progressive telomere shortening in vitro, also have extensive changes in splicing 88 
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2.  AIMS OF THE THESIS 
 
The overall aim of this thesis was to obtain a deeper understanding of the potential 
relationships that link the genetic mechanisms found in HGPS to those occurring in 
normal physiological aging. 
 
The specific aims were as follows: 
 
Paper I. w Develop an absolute quantification method for the LMNA locus
 transcripts. 
 w Quantify the expression of LMNA locus transcripts and proteins 
 during in vitro cell aging in samples from HGPS patients and unaffected 
 donors. 
 w Determine the presence and expression of progerin in cells from 
 unaffected donors during in vitro cell aging. 
 
Paper II. w  Evaluate progerin as a potential biomarker for aging. 
 
 w Quantify the amount of progerin-expressing cells during in vitro cell 
 aging in different age groups of unaffected donors. 
 
Paper III. w Develop an allele-specific absolute quantification assay for the 
 LMNA gene. 
 w Determine whether the LMNA gene has differential gene expression for 
 different alleles to test our hypothesis that high- and low-expression 
 alleles may contribute to the phenotype variability in laminopathies. 
Paper IV.  w Investigate the potential effect of physiological aging on splicing in 
several tissues of normal aging mice. 
 w Determine which pathways and biological functions are most 
 affected by age-related splicing during physiological aging in normal 
 aging mice. 
w Investigate whether the splicing machinery presents signs of decay 
during the physiological aging of normal aging mice. 
 w Investigate the potential effect of the expression of the 
 HGPS mutation on splicing in progeria mice. 
 w Determine which pathways and biological functions are most 
 affected by HGPS-induced splicing.  
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3. MATERIAL AND METHODS 
 
Material and methods used in this thesis are described in more detail and with specific 
information for each study in the corresponding section of each paper. Here we present 
an overview of these and include some extra information not available in the papers. 
 
3.1 LABORATORY ANIMALS 
 
3.1.1 Animal housing  
Mice were bred in-house and accommodated in the experimental animal facility 
(Karolinska Hospital, Huddinge, Sweden). The housing conditions included a 12-hour 
light/dark cycle, a temperature of 20-22 °C and 50-75% air humidity. Mice were 
supplied with R36 pellets (Lactamin, Sweden) and drinking water ad libitum. Animal 
studies were approved by the Stockholm South Ethical review board (Stockholms 
Södra Djurförsöksetiska Nämd), Dnr S101-12, S107-09 and S141-06. 
 
3.1.2 C57BL/6J wild-type mice 
Male C57BL/6J wild-type mice were aged up to 4, 18, and 28 months (paper IV). 
When the desired age was reached, the mice were euthanized by cervical dislocation. 
Tissues from a minimum of 5 mice were collected for each age group for RNA 
extraction. Extra care was taken during dissection and collection of tissue to make sure 
that the time ranged between 30-45 minutes and tissues were immediately transferred 
into liquid nitrogen. Tissues were stored at -80°C prior to homogenization and RNA 
extraction. 
 
3.1.3 Body weights, and tissue histopathology 
C57BL/6J wild-type mice were weighted directly after cervical dislocation. Skin, 
skeletal muscle and femurs were fixed over night in 4% w/v paraformaldehyde (PFA), 
(simultaneously with tissue collection for RNA extractions). The following day, 
tissues were transferred into 70% ethanol for preservation until use. Femur length and 
thickness were measured at 3 points and then the bones were decalcified in 12.5% 
EDTA during a period of 3 weeks, before embedding. Tissues were embedded into 
paraffin, sectioned and stained with hematoxylin and eosin. Microscopic examination 
for pathology was performed to discard gross lesions suspected of being tumors or 
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representing major pathological conditions and confirm normal physiological aging 
pathology.  
 
3.1.4 HGPS mice 
An inducible HGPS mouse model with tissue-specific expression of the most common 
HGPS mutation in the skin, was created in our laboratory, FVB/N.Cg-Tg (tetop-
LAG608G, -EGFP) VF1-07; K5tTA114. The HGPS mouse model is based on the tet-
ON/OFF system, which is a binary transgenic system composed of a transactivator 
(tTA or rtTA), under the control of a tissue-spcific promotor, and a target gene located 
downstream of a tet-op. When the transactivator is present it binds to the tet-op and 
induce expression of the target gene. A second dimension of the tet-ON/OFF system is 
that it is tetracycline responsive which make it possible to either turn-on or off the 
transgenic expression of the target gene, simply by adding doxycycline, a tetracycline 
derivate, to the mice drinking water 115 116. Gene expression of the HGPS mutation in 
skin of our transgenice HGPS mice in paper IV was controlled via the Tet-Off system 
(fig.6). 
 
 
Figure 6. Schematic illustration of the regulation of the expression of the target gene with the tet-Off 
system.  
 
To generate HGPS mice, transgenic mice that carried the target gene, a minigene of 
human lamin A with the LMNA c.1824C>T, p.G608G mutation (tetop-LAG608G), 
where intercrossed with transgenic mice carrying the keratin 5 transactivator 
(K5tTA)117 (fig.7). Intercrossed breedings were performed with doxycycline supplied 
Tet-Off   
Specific promotor tTA  
Dox tTA  
Dox 
Transcription of  
 the Target gene 
pTRE Target gene pTRE Target gene 
tTA  
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in the drinking water, which was removed at day of birth to induce transgenic 
expression, in binary transgenic offspring, of human lamin A and progerin within the 
first postnatal week Sagelius114 118. Keratinocytes were isolated from these HGPS mice 
118 to be used in paper IV. 
 
 
Figure 7. Constructs containing the lamin A minigenes. Schematic illustration of the lamin A 
constructs. Both constructs contain a responsive pTRE element (tetop), which regulates the expression 
of the downstream gene in the presence of a transcriptional transactivator. Construct LA, tetop-LAwt, 
overexpress human lamin A and construct LAG608G overexpress human lamin A and progerin. 
Tetop=pTRE, IRES=internal ribosomal entry site, eGFP= enhanced green fluorescent protein, poly A= 
polyadelination sequence. 
 
3.1.5 Isolation of keratinocytes 
Primary keratinocytes were isolated from HGPS mice at postnatal days 24 and 35, 
with transgenic expression induced at the day of birth 118. Briefly, animals were 
sacrificed by cervical dislocation, and the fur was trimmed before the skin was taken 
and placed into Ca2+ free PBS (d-PBS; Invitrogen). Subcutaneous tissue was removed, 
and the skin was floated on trypsin (T4424; Sigma-Aldrich) for 2 h at 32°C. After 
incubation, the epidermis was scraped into S-minimal essential medium (S-MEM; 
Invitrogen) supplemented with 0.01% soybean trypsin inhibitor (T9128; Sigma- 
Aldrich) and 0.5% BSA (bovine albumin fraction V solution (7.5%); Invitrogen) and 
gently mixed with a magnetic stirrer at room temperature for 20 min. The cell 
suspension was filtered through a 70-mssenti strainer (BD Falcon, Becton Dickinson, 
Franklin Lakes, NJ, USA), and viable cells were counted after staining with tryphan 
blue. 
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3.2 CELL CULTURE 
 
3.2.1 Cell cultures and growth conditions 
Primary dermal fibroblasts and EBV-transformed lymphoblasts were obtained from 
the Coriell Cell Repositories (Camden, NJ, USA) and from the Progeria Research 
Foundation Cell and Tissue Bank (PRF, Peabody, Massachusetts, USA). Fibroblasts 
were grown in monolayer with Dulbecco's Modified Eagle Medium (DMEM, Gibco) 
supplemented with 15% Fetal Bovine Serum (FBS, Biowest or Saveen & Werner), 
2mM L-Glutamine (Gibco) and 1% Penicillin/Streptomycin (Gibco) in a humidified 
cell incubator at 37°C, 5% CO2. Lymphoblasts were grown in cell suspension in RPMI 
1640 medium supplemented with 2mM L-glutamine, 15% heat-inactivated FBS and 
1% Penicillin/Streptomycin (Gibco) under same incubation conditions as fibroblasts. 
 
3.2.2 In vitro cell aging  
Fibroblasts were aged in vitro by passaging the cells for several passages until they 
had lost their proliferative potential. Fibroblasts cultures were grown until they 
reached 90-100% confluency and then splitted 1:4. Confluent cultures were 
trypsinated with 0.05% Trypsin-EDTA (Gibco) in the cell incubator for 5-10 minutes. 
RNA and proteins were extracted from cells collected at every third passage.  Cells 
were also frozen down at about every third passage to keep a back-up of cells if 
needed. Cells were frozen in 10% DMSO in FBS, and stored at -140°C until use.  
 
3.3 RNA EXTRACTION AND cDNA SYNTHESIS 
 
3.3.1 RNA extraction 
Total RNA was extracted from cells and tissues in Trizol, according to standard 
procedure following the manufacturers protocol (Invitrogen or Ambion). Cells were 
directly lysed in Trizol while tissues were homogenized in Trizol.  RNA pellets were 
dissolved in nuclease-free water (Ultrapure, Gibco) and quantified using a 
spectrophotometer (BioPhotometer, Eppendorf). RNA extracts that were not being 
used for exon arrays were treated with DNase I according to the manufacturer’s 
recommendations (RQ1 RNase-Free DNase kit, Promega). Thereafter, all RNA 
extracts were purified using RNeasy clean-up kit (Qiagen) and quantified again by 
regular OD spectrophotometry. 
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Purified RNA to be used for exon arrays were additionally quantified using a 
NanoDrop spectrophotometer (NanoDrop Technologies, DE, USA) and total integrity 
of RNA extracts was assessed by running aliquots on an Agilent 2100 Bioanalyzer 
(Agilent, CA, USA).  
 
3.3.2 cDNA synthesis 
Purified RNA was reverse transcribed with random hexamers using the SuperScript 
cDNA Synthesis Kits (Invitrogen) and cDNA samples were diluted in nuclease-free 
water and stored at -80°C for long term storage and -20°C for short term storage. 
 
3.4 RT-PCR 
 
Regular RT-PCR was used for gene walking for detection of novel LMNA Isoforms 
(paper I) and for RT-PCR validation of splicing detected with exon arrays (paper IV). 
cDNA was amplified by PCR using Hotstar Taq/Hot Star Taq Plus Polymerase kit 
(Qiagen) with primers designed specific to the  gene target. PCR reaction and cycling 
conditions were optimized for each target. To validate the splicing data obtained from 
the exon arrays, the primers were designed on flanking exons of the putative spliced 
region and positioned to make sure that at least one primer was inside one of the spliced 
exon/s. PCR reactions were performed in a 25 µl reaction volume, including 1-3 µl of 
cDNA template with Hot Star Taq plus Polymerase (Qiagen). Quality of cDNA 
template was checked with amplification of β-Actin and each gene was screened on 
agarose gels for at least 2 different primer combinations  
 
3.5 RELATIVE QUANTITATIVE RT-PCR USING SYBR Green 
 
Relative quantitative real-time RT-PCR  (SYBR Green qRT-PCR) was used to 
validate the gene expression data obtained from the exon arrays (paper IV). Random 
hexamers and Super-Script II Reverse Transcriptase (Invitrogen) were used for cDNA 
synthesis from 800 ng of RNA. cDNA was amplified by real-time PCR using SYBR 
Green master mix. All reactions were run in triplicate, and data was only accepted 
when the variation among the CT value triplicates was < 0.3 units for CT < 30, and < 
0.5 units for CT > 30. To calculate relative changes in gene expression, we used the 
comparative CT method, the 2 ΔΔCT method 119. Data was interpreted as the 
expression of the gene to be validated relative to the reference gene β-actin in progeria 
animals compared to wild-type animals. 
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3.6 ABSOLUTE QUANTITATIVE RT-PCR USING TAQMAN® 
 
Absolute quantitative real-time RT-PCR (Taqman qRT-PCR) was used for absolute 
quantification of the LMNA transcripts (paper I) and allele-specific LMNA transcript 
quantification (paper III). Primer and Taqman MGB probe sets were designed using 
Primer Expresss Software version 2.0. (Applied Biosystems) and Primer version 3.24. 
One primer per amplicon was designed to cover an exon–exon boundary. Real-time 
PCR reactions were performed in a 20 µl reaction volume in triplicates, including 5 µl 
of cDNA template. Each plate contained a minimum of six different dilutions of 
cloned standards for a standard curve. All assays were performed with Taqman 
Universal master mix (Applied Biosystems). The concentration of oligos was initially 
optimized for each amplicon and the same batch of primers (Medprobe), and probes 
were used throughout this study. For endogenous controls, we utilized validated assays 
for β-glucuronidase (GUSB) and ribosomal protein large PO (RPLPO) (Applied 
Biosystems). The plates were loaded on an ABI7500 fast system sequence detection 
instrument and run according the manufacturers cycling recommendations.   
 
3. 4 WESTERN 
Western in combination with densitometry was used in paper I for characterization and 
quantification of LMNA protein isoforms. Proteins were extracted from cells using 
RIPA buffer (that included a cocktail of proteinase inhibitors, Roche). Samples were 
stored at -80°C until usage. Before loading, samples were thawed on ice and diluted in 
16M urea to a final concentration of 1.3 M in a SDS loading buffer (including freshly 
added β-mercaptoethanol). The samples were denatured at 100°C for 5 min. Enhanced 
protein separation was accomplished using Protean II xi cell western blot system 
(Biorad) according to previously described procedure 114 where 20 cm long 4%/7.5% 
discontinuous Laemmli slab gels were used. The gels were run for 13 hours at 20 mA 
using a cooling system at 2°C. Proteins were transferred to a nitrocellulose membrane 
filter (Hybond-C +. Amersham Biosciences) using a Semidry Transfer Cell (Biorad) at 
24 V for 40 min in 20% methanol/200 ml tris/glycine transfer buffer (Biorad). Filters 
were blocked in TBS-T, 5% milk for 45 min at RT. After antibody incubations and 
washings, ECL plus (Amersham Biosciences) was added to the filters for 5 min at RT 
and the filters were exposed to film. 
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3.5 DENSITOMETRY 
 
Protein quantification by densitometry was used in paper I. It was performed on 
Western filters using the Versa Doc Imaging system (Biorad) and analyzed with the 
Quantity One software (Biorad). Relative band intensities were normalized to the 
housekeeping gene brotein quantification by densitometry was used in paper I. It was 
performed on Western filters using the Versa Doc Imaging system (Biorad) 
 
 
3.6 IMMUNOFLUORESCENCE 
 
To analyze protein expression directly on the cell, we used immunofluorescent 
stainings (paper II). Cells were stained with different primary antibodies in 
combination with fluorophore-conjugated secondary antibodies. Fibroblasts, fixed in 
4% PFA were permeabilized with 1% NP-40 (Thermo Scientific) and blocked for 30 
minutes at room temperature using blocking buffer that contained 5% serum (of the 
same animal type as the host for the secondary antibody) and 0.1% Brij 58 detergent 
(Thermo scientific) diluted in DPBS. The primary antibodies were incubated over 
night at +4°C and the secondary antibodies were incubated one hour RT. Cells were 
incubated with DAPI (4'-6-Diamidino-2-phenylindole), 3 min at room temperature for 
counterstaining and mounted with ProLong Gold Antifade Reagent (invitrogen). 
 
 
3.7 EXON MICROARRAYS 
 
The GeneChip® Mouse Exon 1.0 ST arrays (Affymetrix) were used in paper IV to 
analyze alternative splicing in aging mice. Gene Chip WT cDNA Synthesis, whole 
Transcript Sense Target Labeling Synthesis, exon array hybridization, staining and 
scan was performed by the Karolinska Institute B.E.A core facility at the department 
of Biosciences and Nutrition. Five point five micrograms of purified RNA was used 
for the exon array hybridization. Exon array quality control, data analysis and 
detection of alternatively spliced and differentially expressed genes were performed in 
Partek Genomic Suite software.   
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4. RESULTS AND DISCUSSION 
 
4.1 PAPER I 
 
To determine whether progerin was expressed during normal aging, we developed an 
absolute quantification method via real-time RT-PCR to measure the expression levels 
of the LMNA gene transcripts lamin A, lamin C, and lamin Δ150/progerin during the in 
vitro cell aging of primary dermal fibroblasts from HGPS patients, as well as age-
matched and parent unaffected controls. Our main findings showed that the progerin 
transcript was expressed at very low levels in all samples from young and adult 
unaffected controls, which is in agreement with studies that have quantified progerin 
mRNA in normal fibroblast cells83 89. Our results showed that the overall expression 
level of progerin mRNA in normal cells was 160-fold lower than the high expression 
levels found in the HGPS cells. However, a different finding was obtained in one study 
83 that used relative qRT-PCR to demonstrate a 50-fold lower level of expression in 
unaffected fibroblasts. This difference could be attributed to the power of the 
quantification technique, sample variation or processing.  
An additional finding in our study was that the progerin transcript levels increased 
during cellular aging in late passages both in the HGPS samples and the adult unaffected 
controls during in vitro cell aging. Previous studies quantifying progerin protein in cell 
cultures of aging HGPS cells had been done in few samples e.g. 12; our results were in 
agreement with these studies. However, we could not confirm this result for the protein 
using Western blots, most likely due to a high sample variability and limited sensitivity 
in the assay.  
Regarding the increased progerin mRNA levels during cell aging in the late passages of 
our unaffected controls, the increased level was only statistically significant for our adult 
controls but not in aged-matched controls, which could mean that it is easier for cells 
from elder donors to accumulate progerin transcripts; this finding suggests that mis-
splicing occurs more frequently in cells from older donors and could occur even more 
frequently with increased age. However, in contrast with our finding, progerin mRNA 
quantification in cells from unaffected donors of different ages has shown both in vitro 
83 and in vivo 89 that the progerin mRNA levels remain unchanged with age. This 
difference could be attributed to the chosen quantification method or to differences 
between accumulation mechanisms in cellular aging and physiological aging. However, 
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the model of cellular aging in vitro is a valuable tool for studying the molecular 
mechanism of physiological senescence120.  
Regarding the overall expression levels of Lamin A, C and progerin transcripts, we 
found that lamin C was (significantly) the most highly expressed transcript in all 3 
groups. Considering that Lamin A and Lamin C share promotor, our results suggest that 
the splicing efficiency for lamin C is favored and/or the lamin C transcripts are more 
stable. An interesting result was that the lamin AΔ150 expression in HGPS did not 
affect the overall normal lamin A levels. The combined amounts of lamins A and 
AΔ150 were approximately twice to those found in the normal controls. We suggested 
that this could be explained by differences in mRNA stability (with consequences in 
the accumulation of the lamin AΔ150 transcript), differences in splicing efficiency, or 
the upregulation of LMNA gene expression in HGPS cells. There has been little 
research on LMNA mRNA expression; however, in a later study 121, we demonstrated 
the presence of high- and low-expressing alleles in the LMNA gene. Therefore, this 
result could also be explained if the HGPS mutation was always located in another 
high-expressing allele. The increased overall levels of total lamin A (A + AΔ150) in 
HGPS cells could also help to explain the thickened lamina observed in HGPS cells 12. 
However, it is still unclear if progerin accumulates in HGPS due to increased lamin 
AΔ150 expression, its own accumulation or due to the accumulation of progerin.  
We also quantified progerin at the protein level using Western blot and densitometry, 
but the progerin levels in normal cells were either absent in the cells or below the 
detection level; this finding has also been communicated by others 89. Additionally, we 
found that lamin C migrated as a doublet band in our Western blot with enhanced 
protein separation. However, we did not find any evidence for a new lamin C splice 
form (using RT-PCR gene walking). This result could maybe be better explained by 
migration differences due to phosphorylation or other post-translational modifications. 
This observation is important to consider when quantifying progerin on Western blots 
with insufficient separation. In summary, we have shown in this paper that progerin 
mRNA is present in unaffected individuals and that the levels increase during in vitro 
cell aging both in HGPS and in unaffected parent controls, which supports the 
hypothesis of increased progerin expression during cellular aging and suggests a link 
between HGPS and normal aging. Finally, we developed an absolute quantification 
method that is useful for the absolute quantification of LMNA transcripts in HGPS and 
other laminopathies, as well as during aging.  
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4.2 PAPER II 
The primary aim of this study was to on expand on the first study (paper I) to more 
samples from unaffected donors and different age groups, and to quantify the progerin 
protein directly in the cell via immunofluorescence in early and late passages of cells 
aged and passaged in vitro. We used a newly available antibody for progerin and 
related progerin to DNA damage and cellular senescence. Our results showed that 
progerin-positive cells with a clear or well-defined nuclear staining pattern is very 
rarely expressed in cell cultures from unaffected donors. Of 1,000 cells screened per 
analyzed passage, we were only able to detect 1 cell (0.1%) with a clear nuclear 
staining in 2 late passages from one elderly donor. The percentage of progerin-positive 
cells in the passaged cultures from unaffected donors had shown previously that the 
amount of progerin-positive cells in late passages increased up to 1.5% and 3.0%, 
respectively, in 2 different samples from a previous publication from a different lab 
and using a different antibody20. However, their quantification included cells that 
presented diffuse progerin staining surrounding small, highly condensed nuclei that 
were defined as apoptotic cells 20. We also observed these diffuse progerin nuclear 
stainings (ranging from 0-3%) both in cells with condensed nuclei and in dividing 
cells that co-localized with LBR at the same time; however, we did not classify these 
as clear nuclear stainings. These co-localizations were most frequent (approximately 
6%) in the HGPS cells, followed by young and thereafter old unaffected controls.  
Apart from what we observed in the HGPS samples, we did not find any evidence for 
these co-localizations increasing in the late passages of unaffected controls. In this 
context, our results are more similar but are still in disagreement. Our progerin 
staining results in normal cells are more similar to those of McClintock et al (2007)89, 
that found that fibroblast cultures derived from young subjects had 0.01% progerin-
positive cells, while cultures derived from elderly subjects had an average of 0.3-0.8% 
progerin-positive cells; the amount of progerin-positive cells was lowered when the 
progerin-positive cells were quantified in vitro for the same subjects. Moreover, in 
their study, most skin sections from unaffected individuals did not have progerin-
positive cells, and the distribution of positive cells in the skin was not random. 
Additionally, McClintock et al  (2007)89 presented cultured progerin-positive cells in 
which at least some of the cells stained could be interpreted to have 
cytoplasmic/diffuse nuclear staining. Considering the above findings, the amount of 
screened cells and the nature of the quantified progerin staining could help explain 
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why it was so difficult to find cells with well-defined nuclear progerin staining in our 
cultures of unaffected cells; this could also explain the differences observed between 
these studies20; 89 and results in paper II. 
Due to the extremely low level of progerin-positive cells with clear nuclear staining in 
the cultures of normal cells, we failed to quantify the progerin-positive cells in the 
early and late passages of the cells aged in vitro.  However, the fact that the progerin-
positive cells with clear nuclear staining was found in a late passage from an elderly 
donor is in agreement with the expected increase of progerin with age and during 
cellular senescence, as observed by McClintock et al (2007)89, who found that this 
increase was slight but doubled from 0.4-0.8% within 5 passages. A very recent study 
failed (with the same antibody that we used ) to detect progerin in the cell cultures of 
unaffected young and old individual, and centenarians122, confirming that the presence 
of progerin-positive cells in culture is extremely rare.  
Regarding progerin in HGPS cultures, we found that the average amount of progerin-
positive cells increased from approximately 70% in the early passages to nearly 90% 
in late passages, confirming the results of previous studies12; 14; 75. We observed that 
the progerin staining was localized both to the nuclear rim and nucleoplasma in early 
passages, while in late passages, there was a nucleoplasmic depletion of progerin and a 
thickening of the lamina (with the involvement of progerin). This is agreement with 
what has been observed with the lamin A/C antibodies in HGPS cells 12 and suggests 
that the direct increased incorporation of progerin to the nuclear lamina contributes to 
its thickening. We also observed typical cellular phenotypes for the HGPS cells that 
have previously been described, such as increased nuclear blebbing, binucleated nuclei 
and giant cells. However, we have not yet quantified these features. 
To relate our results to DNA damage in our cell cultures, we quantified the DNA 
damage in HGPS and in our unaffected controls. γH2AX-positive cells were detected 
in all passages, with the lowest amounts present in the early passages of samples from 
young unaffected and young HGPS samples (near 20% in both); the highest number of 
cells with DNA damage was unexpectedly found in late passages of our adult 
unaffected controls (approximately 60%). However, the amount of cells with increased 
DNA damage in late passages was observed in all 4 groups but was only significant in 
the young unaffected controls and HGPS, which was likely due to higher variability 
between the samples of the adults and old controls. We also quantified the cells that 
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had clear distinguishable DNA damage foci at the power of resolution used. Again, the 
amount of cells with 1-2 foci was highest (near 50%) in the late passages of the 
unaffected adults; the foci increased (3-5) in the late passages of HGPS and old 
unaffected but was not significant in the young and adult groups. And was, in turn, 
more frequent in the old unaffected group. In summary, the DNA damage presented a 
considerable variability between samples with a tendency to increase during in vitro 
cell aging.  
 
4.3 PAPER III 
The primary goal of this study was to develop an allele-specific quantification assay 
for LMNA transcripts and to determine whether the LMNA gene presented allele-
specific expression, which could then help explain the phenotypic variability observed 
in HGPS patients and other laminopathies that arise from the same mutations. For this 
purpose, we used one of the few polymorphic LMNA SNPs (rs4641 C/T) that we 
genotyped both in the HGPS and unaffected fibroblast cultures and developed an 
allele-specific absolute quantification method for the lamin A and lamin C transcripts. 
Our results show that the LMNA gene presented allele-specific expression with the 
presence of high- and low-expressing alleles. The C allele was the most frequently 
expressed allele and corresponded to 70% of the total transcription for lamin A and 
lamin C transcripts. Studies investigating the nature of LMNA expression and, in 
particular, allelic expression have been poor; to our knowledge, there has been only 
one report studying the differential expression of the alleles in the LMNA gene123; 
Reddel and Weiss (2004) studied the wild-type and mutant allele in HGPS and 
controls and, via sequencing and fragment analysis RT-PCR, found no major 
differences between these alleles; the HGPS mutant allele was slightly less expressed 
(47%). The sequencing of more LMNA haplotype variants may help to identify new 
differentially expressed alleles in the LMNA gene. The aberrant splicing mechanism in 
HGPS raises questions regarding the splicing efficiency and allele-specific expression 
of this disease. Therefore, we analyzed the samples that were quantified for progerin 
from our previous study75 (this thesis paper I) for the existence of a correlation 
between higher progerin transcript levels and the allelic localization of the HGPS 
mutation. We found that the HGPS mutation could be located in either the T or C 
allele. We were not able to relate the localization of the HGPS mutation to disease 
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severity due to a lack of clinical information for the majority of our samples. 
Nevertheless, personal communication with the Progeria Research Foundation 
confirmed that 2 of their classical HGPS samples that we had analyzed, (and in which 
the HGPS mutation resided in the low-expressing allele) had been graded as less 
severe, suggesting a possible role of allele-specific LMNA expression in the disease 
severity of HGPS. Further investigation using our method in clinically classified 
HGPS samples will help to answer the importance of this SNP in the pathological 
development of this disease. Interestingly, a recent study124 identified this SNP as part 
of a haplotype that is significantly associated with longevity in long-lived humans. It 
would therefore be of particular interest to use our method and quantify these alleles in 
cDNA samples from centenarians. In summary, we have developed a powerful allele-
specific assay for the LMNA gene that may be useful in studying and explaining the 
phenotypic variability, disease development and severity of laminopathies, premature 
aging and the possible difference in the impact of these alleles and/or progerin 
expression during longevity. 
 
4.4 PAPER IV 
The primary aim of this study was to investigate the effect of physiological aging 
splicing globally. Our results showed that there is a considerable amount of genes that 
are alternatively spliced in all tissues analyzed of mice. This is in agreement with other 
recent in vivo studies that have shown an effect of age on alternative splicing in human 
brain 111; 112 and human peripheral blood leukocytes113. The amount of alternatively 
spliced genes varied between different tissues, which is expected due to the well-
known fact that splicing in general is tissue specific. We also showed that the amount 
of alternatively spliced genes increased with age and varied significantly between 
different tissues and periods of the physiological aging process. Skin was in particular 
interesting; while alternatively spliced genes were not found between the period of 4-
18 months, on the contrary during the later aging period 18-28 months, the same tissue 
presented a great amount of spliced genes. These results suggested that age-dependent 
alternative splicing, increased with age but the start-off and magnitude of this splicing 
is different between tissues. Taking into consideration the total amount of alternatively 
spliced genes during the whole aging period 4-28 months, varying from 1247 to 1886 
genes between different tissues this corresponded to 13-30% of the total amount of the 
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genes analyzed (non-differentially expressed genes) and to 3-9% of the total amount of 
genes represented on the exon arrays. This can be compared with a recent study112  in 
human brain using high throughput sequencing were they found that nearly 40% of the 
genes that were expressed in human brain had changes in splicing over postnatal life. 
Of these 70% occurred during development and 30% during aging, which means that 
12% of the total amount of genes expressed in brain had aging-related splicing. 
Considering the variation of age-related splicing that we have shown in our normal 
aging mice, our results could be in very well agreement with this study. To our 
knowledge, we are the first to show that the amount of age-related splicing also 
increased with advancing age, however never reaching a global effect genome-wide. 
That the focused nature of age-related splicing was restricted to roughly a tenth of the 
coding genes did not argue for a random global effect of age over splicing and might 
speak in part against a general decay of the splicing machinery. However, these genes 
could be more prone to potential acquired splicing deficiency with less stringent splice 
sites. One important question that remains to be answered is whether this increased 
splicing with age corresponded to aberrant splicing generating deleterious proteins or 
if it is part of a normal and regulated mechanism. The used exon arrays are not 
designed to detect the progerin transcript, so the LMNA was not detected as an 
alternatively spliced gene with age. 
When we analyzed which biological functions and pathways that were enriched with 
alternatively sliced genes across all tissues, we found to our surprise that RNA 
processing including RNA splicing was the biological function most significantly 
affected with age-related splicing. In addition, the spliceosome also resulted to be 
significantly enriched with spliced genes. This means that the splicing machinery is in 
particular affected by age-related alternative splicing which speaks for that the splicing 
machinery could be affected. A recent study 113, using transcriptomic microarrays has 
shown, that in human blood there is an effect of age on RNA processing looking into 
pathway enrichment of genes with age-associated transcripts, which gives further 
support to our finding in mice. Their and our study together demonstrated that RNA 
processing, including RNA splicing is altered during normal physiological aging of 
both mice and humans. Our results directly implicate the spliceosome with 
alternatively spliced genes coding for important components of the spliceosome, 
majorly snRNAs but also spliceosome proteins (Wbp11 Prp19, and Prp43). In the 
spliceosome, the snRNAs, along with their associated proteins, form ribonucleoprotein 
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complexes (snRNPs), which bind to specific sequences on the pre mRNA substrate 125 
yielding the spliceosome its catalytical competence126. This suggests that alternative 
splicing of spliceosome snRNA during aging, if not aberrant/deleterious to the 
splicesome, could still potentially have consequences on its specificity and splicing 
catalysis of specific genes. Explorative network analysis of alternatively spliced genes 
across all tissues identified RNA post-transcriptional modifications as the most 
significant network associated function.  Two other less significant network associated 
functions were Dermatological diseases and conditions, and infectious disease with the 
NF-κB complex as a central node. NF-κB refers to a family of transcription factors 
with pro-inflammatory functions implicated in diverse disease and pathologies and 
biological processes. Interestingly, the IKK/NF-κB signaling pathway has been 
proposed to be one of the key mediators of aging. NF-κB can be activated secondarily 
to DNA damage via the DNA response protein ataxia telangiectasia mutated (ATM) 
127; 128. In turn, the regulation of NF-κB activation is mediated by the IKK complex of 
cytoplasmic kinases. In our explorative network, the RNA post-transcriptional 
modification functions connect to the NF-κB complex node via the nuclear RNA 
export factor 1 (NXF1) and DEAD (Asp-Glu-Ala-Asp) box helicase 3, X-linked 
(DDX3X) genes (see figure 4A, paper IV). The encoded protein of NXF1 shuttles 
between the nucleus and the cytoplasm and binds in vivo to poly(A)+ RNA and is 
involved in nuclear export of mature mRNA to the cytoplasm129. Alternative splicing 
seems to be a common mechanism of this gene. DDX3X is a RNA helicase involved in 
several steps of gene expression, such as transcription, mRNA maturation, mRNA 
export and translation and interacts directly with NXF1 and may be involved in 
nuclear export of specific mRNA 130.In turn, NXF1 expression in Jurkat T-cells have 
shown to activate the NF-kB. This allowed us to speculate that the age-related 
alternative splicing of NXF1 could potentially contribute to activate the NF-κB 
complex in several tissues. 
 
 We also investigated if same changes observed with alternative splicing occurred with 
differential expression of genes with age, but did not find any evidence for 
differentially expressed genes to be involved in RNA processing. Transcriptomic gene 
expression studies in humans have had low reproducibility du to the usage of different 
analysis platform, low tissue availability, low sample number and cell type 
heterogeneity. However, common signatures for aging across tissues and species in 
mice, rat and humans that have been found within the top- categories for altered gene 
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expression with age have been related to the immune response, including complement 
activation, antigen processing by the lysosome, apoptosis and anti-apoptosis 
pathways131. Although gene expression was not the main focus of our study, our 
results were in agreement with this study, because our top KEGG-pathways enriched 
with differentially expressed genes, corresponded to the complement and coagulation 
cascades in skeletal muscle, ECM-receptor interaction pathway in bone, and the 
Cytokine-cytokine receptor interaction pathway in thymus. 
A secondary aim of this study was to independently analyze alternative splicing as an 
effect of the HGPS mutation in keratinocytes of a progeria mouse model created in our 
laboratories. Our results showed that the main variance in the exon arrays was 
represented by the age/development stage (24 days versus 35 days) and secondarily by 
genotype (wild-type versus HGPS mice). The highest amount of alternatively spliced 
genes was found during normal development. Strikingly, if compared to the results 
observed during normal tissue aging this corresponded at least to a double amount of 
genes alternatively spliced during normal development in comparison to normal aging. 
This could in part be due to a pure cell type analyzed in progeria mice, while in normal 
aging whole tissue skin was analyzed, but much probably as it has been described 
above, during whole life span 70% of the age-related splicing correspond to 
development and the rest to proper aging 112. When comparing the same 
developmental period in bi-transgenic progeria keratinocytes extracted from HGPS 
mice, the amount of alternatively spliced genes decreased. This suggested that the 
expression of the HGPS mutation could have an effect on normal developmental 
splicing or could simply be reflected by the different phase of hair-cycle, where in the 
wild-type mice the majority of the skin would likely be in early anagen phase at 
postnatal day 24, and late anagen or early catagen phase at postnatal day 35 132. When 
we compared the amount of genes that were alternatively spliced between wild-type 
and progeria mice we found that as expected (since the accumulation of progerin with 
time is central in the disease pathology), that the amount of alternatively spliced genes 
as effect of the HGPS mutation was higher after 35 days of postnatal transgenic 
expression and alternatively spliced genes were implicated in the ECM-receptor 
interaction pathway. ECM (Extra Cellular Matrix) components have been described to 
be the second largest group of genes misregulated in cultured HGPS cells16. 
Aditionally, the inability to produce a functional ECM has ben proposed to cause 
proliferative arrest in a mouse model for progeria due to defective Wnt signaling that 
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affects affects the ECM.133; 134 Our study gives additional evidence for alterations of 
the ECM composition via alternative splicing. Interestingly, as in normal aging mice, 
an NF-κB central node was also identified in network analysis of alternatively spliced 
genes for our progeria mice, suggesting that alternative splicing might contribute to 
aging through activation of NF-κB both in physiological aging and progeria. Our 
results are in agreement with previous studies that have found in fibroblasts of HGPS 
patients increased levels of NF-κB activation and increased inflammatory gene 
expression when compared to aged-matched controls135 and in a recent study of same 
progeria mouse model that has been used in this thesis, but with embryonic expression 
of the HGPS mutation 136. 
In summary our results showed that during physiological aging of normal mice, there 
is focused age-related splicing that increases in all tissues analyzed with age. These 
genes are mainly involved in RNA processing and in the spliceosome pathway, with a 
potential effect on activation of the NF-κB complex. In addition, we showed that the 
HGPS mutation reduces the amount of genes that are normally spliced in keratinocytes 
during mouse development, and expression of the HGPS mutation induced alternative 
splicing that mainly affected the ECM and potentially also the activation of the NF-κB 
complex. 
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5. CONCLUSIONS  
Paper I. w   We have developed a powerful method that enables the absolute  
 quantification of LMNA locus transcripts. 
 
w We determined the presence and quantified the expression of lamin 
 AΔ150/progerin transcript in HGPS and normal cells and showed that the 
levels in normal cells were   160-fold lower when compared to the levels in 
HGPS cells.  
 
w We showed that the levels of the lamin AΔ150/progerin transcript 
 increased during in vitro cell aging in fibroblasts from both HGPS 
 patients and adult unaffected donors. This suggest a common genetic 
mechanism in HGPS and normal physiological aging. 
  
 w We showed that the lamin C transcript, was the highest expressed LMNA 
 transcript.  
 
w We showed that the expression levels of the  lamin AΔ150/progerin in 
HGPS did not affect the level of lamin A transcripts since the total 
lamin A transcript levels  (lamin A + progerin) were doubled in HGPS 
compared to normal cells. 
 
 
Paper II. w We found that progerin-expressing cells with clear nuclear staining were 
  very rare in primary fibroblast cultures from unaffected donors, both in 
early and late passages.  
 
 
 w  Our results question the physiological relevance of progerin during 
 physiological aging since fibroblasts from unaffected donors only showed 
 clear nuclear staining in at  the most 0.1% of the cells. 
 
 
Paper III. w We have developed a powerful allele-specific absolute quantification 
assay for the LMNA gene.  
 w We established that the LMNA gene has high and low expressing 
 alleles and showed that the SNP rs4641 C allele was expressed more 
 frequently, which corresponded to 70% of the total lamin A/C 
 transcripts.  
 w Our results might explain the differences seen in HGPS disease 
 severity and the phenotypic variance among laminopathies  
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Paper IV.  w We showed that physiological aging has a focused effect on alternative 
splicing, when analyzed genome-wide,  and that alternative splicing was 
increased with age in all  tissues analyzed. 
 w Our results showed that alternative spliced genes across all tissues 
 were mainly involved in RNA processing and the spliceosome pathways, 
 with a potential effect on splicing specificity and catalytic activity.  
w We showed that the expression of the HGPS mutation reduced the 
amount of genes that were alternatively spliced during normal 
development and induced alternative splicing of genes involved in the 
extra cellular matrix- receptor interaction pathway. 
 wWe identified NF-κB as a common node in explorative networks of 
 alternatively spliced genes, independently, in both physiological aging of 
 normal mice and in keratinocytes from HGPS mice.  
 
6. FUTURE PERSPECTIVES  
Many studies points towards a potential link between pathological aging in HGPS and 
physiological aging, however many questions still remains. Increased levels of progerin 
transcripts during cellular senscense and an increase in the number of progerin positive 
cells during cellular aging and in senescense during physiological aging has been hard to 
demonstrate conclusively due to the low frequency of cells expressing progerin both in 
vivo and in culture. One important question is if this low frequency is relevant for 
physiological aging. McClintock and co-workers, have suggested that the cells in vivo 
corresponds to a specific subpopulation of terminally differentiated/senescent cells 89.  It 
would therefore be of interest to closer analyze these cells and characterize them. FACS 
analysis of progerin positive cell could for instance help to analyze a larger population 
of cells, by sorting out those few cells expressing progerin and at the same time 
determine their state of differentiation. Of particular interest would be if some of these 
cells present stem cell features, since this could maybe help to explain the effect from a 
small progerin-expressing cell population on physiological aging.  
An other question is whether the increased progerin mRNA during cellular aging 
corresponds to the summary of a global low expression in all cells in culture (below the 
detection level for IF or if it corresponds to progerin mRNA being expressed only in the 
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few cells that presents nuclear progerin staining (within the detection limit for IF). 
FACS analysis of these cells and single cell RNA sequencing could help to answer that 
question and at the same time investigate if these cells express progerin due to a somatic 
mutation of the LMNA gene rather than a sporadical use of the cryptic splice site. Other 
studies analyzing the expression of progerin during aging of normal cells in additional 
tissues are needed. Another important question to resolve is if an increase in the amount 
of progerin-expressing cells during normal aging is a result of increased use of the 
cryptic splice site or a constant usage with lamin AΔ150/progerin accumulation only in 
a few cells. Therefore, an important aspect to investigate would therefore be to analyze 
progerin mRNA turnover in progerin-expressing cells. However, it seems that progerin 
will not help to explain aging of the brain tissue since HGPS patient do not present an 
aging phenotype in the brain 6 8. This could most probably explained due to that lamin A 
is not preferentially expressed in the brain, showing far lower expression of lamin A in 
the central nervous system than in peripheral tissues137. (Aditionally, it has been shown 
that prelamin A and lamin A expression in the brain is regulated by miR-9 137; 138 and 
miR-9 overexpression reduce lamin A expression in HeLa cells with no effect on 
lamin C 137.  Moreover, overexpression of progerin in the hippocampus with 
consequence of dramatic nuclear blebbings does not  lead to any obvious pathological 
neurodegenerative phenotype in HGPS mice which suggests that post-mitotic cells are 
less sensitive to the toxic effect from progerin expression 139. 
Addional research is needed to evaluate the significance of progerin and the lamina 
during normal aging. For example, to investigate progerin expression in additional 
tissues during normal aging, in progeria animal models and maybe even in centenarians. 
A recent study of centenarians showed that progerin is not expressed neither in 
centenarians, young or old unaffected individuals, while prelamin A increase with age 
and showed very high expression in centenarians122. This speaks for that the uncleaved 
farnesyl group is not so toxic as previously thought and could even be involved in 
longevity. The toxic effect of progerin would therefore rather come from other farnesyl-
independent interactions such as with the lamina associated domains (LADs) in the 
chromatin, telomeres,  and other lamins and proteins in the lamina.  Therefore it would 
be of interest to investigate if pre-lamin A levels decrease during normal physiological 
aging in vivo. However, targeting isoprenylcystein methylation of the farnesylated 
cysteine of the terminal CAAX motif, by reducing the expression and activity of Icmt, 
ameliorates disease in a progeria mouse model indicating that it is not the farnesyl group 
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alone but also its methylation that is important in the pathology of progeria mice140 . 
We have shown that LMNA gene have allele-specific expression with high and low 
expressing alleles. Further investigation using our method in clinically classified 
samples from HGPS patients and individuals with other laminopathies will help to 
answer the importance of this SNP rs4641 or of its haplotype in the pathological 
development of these diseases. Interestingly, a recent study124 identified this SNP as 
part of a haplotype that was significantly associated with longevity in long-lived 
humans. It would therefore be of particular interest to use our method and quantify these 
alleles in centenarians. Additionally, it also remains to be investigated if the rs4641 SNP 
is linked to other SNPs upstream in the same haplotype block, possibly in the promotor 
or enhancer region. 
To further understand the common mechanisms shared by normal aging and HGPS, it 
is important to continue to establish common cellular and molecular pathologies that 
are caused by progerin and being present in both normal physiological aging as well as 
progeria. Whether progerin has a major role in driving senescence forward at the 
organismal level, or if it is a by-product of aging as a consequence of accumulated 
DNA damage deserves to be further explored. We have shown that splicing is altered 
during normal physiological aging primarily affecting RNA processing and the 
spliceosome, but could also include progerin. Intrestingly, a recent study showed that 
splicing is altered during senescense induced by telomere-dependent progerin 
production 88. In addition we have shown that the HGPS mutation in mice induce 
altered splicing during normal development. Therefore, it would be of interest to 
further investigate if progerin induce age-related splicing in normal physiological 
aging. For instance we could extract RNA from progerin expressing cells and 
investigate by high-throughput sequencing altered splicing in other tissues of progeria 
mouse models, such as vascular smooth muscle cells, fibroblasts and endothelial cells 
of the arteries, osteoblasts in bone, in HGPS fibroblasts and lymphoblasts, and 
vascular smooth muscle cells. To investigate if age-related splicing induce progerin 
production, we could also further analyze our alternatively spliced genes in the 
spliceosome, and overexpress the different candidate splice variants in cells and then 
quantify progerin mRNA expression to see which splice variants make a difference, or 
create splice-reporter for our different splice variants and investigate if old cells 
activate same splicing observed with our exon arrays. 
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It is also of importance to determine whether altered splicing during normal aging 
corresponds to aberrant splicing or to natural regulated splicing with age with specific 
functions in the modification of the RNA processing. Therefore experiments should be 
designed to measure splicing efficiency and accuracy of the splicing machinery, in 
addition to determine if novel or aberrant splicing occur during normal physiological 
aging. 
Finally, our and others observations that NF-κB kappa is a activated both during 
normal physiological and in HGPS pathological aging encourages us to direct our 
attention to search for common upstream NF-κB activators in HGPS and normal 
physiological aging, that are in turn activated by the production of the Hutchinson-
Gilford progeria syndrome mutant protein: progerin. For instance it has been reported 
that accumulation of prelamin A isoforms at the nuclear lamina triggers an ATM- and 
NEMO-dependent signaling pathway that leads to NF-κB activation and treatment 
with NF-κB inhibitors resulted in an improved phenotype in mice with prelamin A 
accumulation141; 142. Of particular interests for our study would be to further investigate 
if the splice forms and increased gene expression of the alternatively spliced genes that 
were identified in our explorative network analysis (and that connected to the NF-κB 
complex DDX3X and NXF1), have an impact on NF-κB activity and inflammation. 
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